Bitget App
Trade smarter
Buy cryptoMarketsTradeFuturesStocksEarnInstitutionAI & More
Technical Analysis: Bearish Trend in Gold Continues, a Break Below $4,700 May Accelerate Downside

Technical Analysis: Bearish Trend in Gold Continues, a Break Below $4,700 May Accelerate Downside

汇通财经汇通财经2026/04/09 06:20
Show original
1. The 4-hour chart shows that spot gold remains below the 200-period simple moving average and has failed to break through the 50% Fibonacci retracement level from the March decline, with the bearish bias remaining intact. MACD has slipped into negative territory, and RSI is hovering around a neutral level of 52, indicating that bullish momentum is weakening. Once the $4700 level is decisively breached to the downside, gold prices may accelerate lower. 2. The initial support below is near the 38.2% Fibonacci retracement (around $4604), with further support at the 23.6% retracement (around $4411) and the previous swing low region (close to $4100), where buying interest is expected to increase. 3. On the upside, initial resistance is near 4732, with further resistance at the 50% Fibonacci retracement level of $4760; a stronger resistance zone lies in the $4897-4915 region (where the 200-period moving average and 61.8% retracement coincide); higher resistance points to the psychological barrier at $5000.
0
0

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.
Trade now!

You may also like

Goldman Sachs comments on AMD (AMD.US) Q3 performance: Data center CPU and GPU show strong performance, growth visibility for 2027 is clear

Goldman Sachs released a research report maintaining a "Buy" rating on AMD (AMD.US) with a 12-month target price of $675.

智通财经•2026/11/04 03:53

AbbVie (ABBV.US) expands Oxford R&D facility in UK, betting on innovation in immunology, neuroscience, and oncology drugs

AbbVie announced on Wednesday that, as part of an investment plan exceeding 120 million pounds (approximately $161 million), the company has expanded its research and development facility in Oxford, United Kingdom.

智通财经•2026/11/04 02:51